Los Angeles Capital Management LLC Has $61.54 Million Stock Holdings in Stryker Corporation (NYSE:SYK)

Los Angeles Capital Management LLC decreased its position in Stryker Corporation (NYSE:SYK - Free Report) by 0.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 165,321 shares of the medical technology company's stock after selling 1,446 shares during the quarter. Los Angeles Capital Management LLC's holdings in Stryker were worth $61,541,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital A Wealth Management LLC purchased a new stake in Stryker in the fourth quarter worth about $26,000. Goodman Advisory Group LLC purchased a new stake in Stryker during the first quarter worth $32,000. City Holding Co. increased its position in Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in Stryker during the 1st quarter worth approximately $40,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Stryker during the 4th quarter worth $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.0%

NYSE SYK traded down $0.06 on Friday, reaching $388.84. The stock had a trading volume of 1,716,294 shares, compared to its average volume of 1,351,495. Stryker Corporation has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a current ratio of 1.64, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $148.42 billion, a price-to-earnings ratio of 52.55, a P/E/G ratio of 2.94 and a beta of 0.91. The business has a 50 day moving average price of $385.67 and a 200 day moving average price of $378.06.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.74% and a net margin of 12.31%. The firm had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same period last year, the business posted $2.50 EPS. The business's revenue was up 11.9% compared to the same quarter last year. On average, analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's dividend payout ratio is currently 45.41%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Roth Mkm boosted their target price on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Citigroup reissued a "buy" rating and set a $455.00 target price (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a report on Friday. BTIG Research reissued a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Finally, Sanford C. Bernstein set a $450.00 price objective on Stryker in a report on Monday, May 5th. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $428.55.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director directly owned 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.20% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.